As a result, our center is performing a phase 2 trial to explore whether induction immunochemotherapy (regimen: sintilimab, albumin-bound paclitaxel, cisplatin) can improve the R0 resection and pCR rates for BR-ESCC patients (ClinicalTrials.gov identifier: NCT04548440). The gene discussed is ALB; the disease is esophageal squamous cell carcinoma.